The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York RFK Jr pushes for FDA approval of BPC 157 peptide Eric Topol, MD posted on the topic LinkedIn FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn Is BPC 157 Banned? Oral vs. Injectable Forms Explained